Vicki Sung

Vicki Sung has over 23 years of work experience in the biopharmaceutical industry. Vicki is currently serving as the VP of Nonclinical Development at Aditum Bio since June 2021. Prior to that, they held the position of VP of Translational Medicine at Arch Oncology from March 2018 to June 2021.

Vicki worked at Celgene for over 10 years, starting in November 2007. Vicki held various roles during their tenure, including Sr Scientist, Assoc Director, and Director. Before joining Celgene, they worked at the Novartis Institutes for BioMedical Research (NIBR) as a Principal Scientist from 2003 to 2007.

Prior to their time at NIBR, Vicki worked at Sugen/Pharmacia/Pfizer as a Scientist from 1998 to 2003. Vicki also had a brief stint as a Post-doctoral Fellow at Stanford University in 1998.

Overall, Vicki Sung's experience spans across different areas of the biopharmaceutical industry, with a focus on nonclinical development and translational medicine.

Vicki Sung holds a PhD in Cell Biology and Anatomy from Georgetown University School of Medicine. Prior to this, they completed their undergraduate studies at the University of California, Berkeley, where they obtained a BA in Integrative Biology.